These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11826742)

  • 41. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.
    Merkel PA; Clements PJ; Reveille JD; Suarez-Almazor ME; Valentini G; Furst DE;
    J Rheumatol; 2003 Jul; 30(7):1630-47. PubMed ID: 12858472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis.
    Calguneri M; Apras S; Ozbalkan Z; Ertenli I; Kiraz S; Ozturk MA; Celik I
    Clin Rheumatol; 2003 Oct; 22(4-5):289-94. PubMed ID: 14579158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Renal involvement in systemic sclerosis].
    Guerini S; Cavazzana I; Venturelli C; Rozzi M; Turina S; Sottini L; Tardanico R; Franceschini F; Scolari F
    G Ital Nefrol; 2007; 24(4):295-310. PubMed ID: 17659501
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pulmonary arterial hypertension. Part II: Medical and surgical treatment].
    Manes A; Marinelli A; Palazzini M; Negro L; Leci E; Gambetti S; Bachetti C; Beciani E; Conficoni E; Branzi A; Galiè N
    G Ital Cardiol (Rome); 2009 Jun; 10(6):366-81. PubMed ID: 19603608
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [New trends in diagnosis and treatment of systemic sclerosis].
    Becvár R; Stork J; Jansa P
    Vnitr Lek; 2006; 52(7-8):712-7. PubMed ID: 16967613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Scleroderma--clinical and pathological advances.
    Denton CP; Black CM
    Best Pract Res Clin Rheumatol; 2004 Jun; 18(3):271-90. PubMed ID: 15158741
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma.
    Johnson SR; Feldman BM; Pope JE; Tomlinson GA
    J Rheumatol; 2009 Feb; 36(2):323-9. PubMed ID: 19040308
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcome measures in rheumatologic clinical trials and systemic sclerosis.
    Furst DE
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v29-30. PubMed ID: 18784136
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pulmonary arterial hypertension in connective tissue disease].
    Cottin V
    Rev Mal Respir; 2006 Sep; 23(4 Suppl):13S61-72. PubMed ID: 17057632
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic sclerosis - continuing progress in developing clinical measures of response.
    Furst D; Khanna D; Matucci-Cerinic M; Clements P; Steen V; Pope J; Merkel P; Foeldvari I; Seibold J; Pittrow D; Polisson R; Strand V
    J Rheumatol; 2007 May; 34(5):1194-200. PubMed ID: 17477486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Systemic sclerosis].
    Villiger PM
    Ther Umsch; 2008 May; 65(5):283-7. PubMed ID: 18622933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic sclerosis: hypothesis-driven treatment strategies.
    Charles C; Clements P; Furst DE
    Lancet; 2006 May; 367(9523):1683-91. PubMed ID: 16714190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic sclerosis/scleroderma: a treatable multisystem disease.
    Hinchcliff M; Varga J
    Am Fam Physician; 2008 Oct; 78(8):961-8. PubMed ID: 18953973
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Current treatment of systemic sclerosis. Part I. Immunosuppressive treatment].
    Sicińska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):192-5. PubMed ID: 18942346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Old medications and new targeted therapies in systemic sclerosis.
    Nagaraja V; Denton CP; Khanna D
    Rheumatology (Oxford); 2015 Nov; 54(11):1944-53. PubMed ID: 25065013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of generalized systemic sclerosis.
    Torres MA; Furst DE
    Rheum Dis Clin North Am; 1990 Feb; 16(1):217-41. PubMed ID: 2406809
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Systemic sclerosis. Which therapies?].
    Bettoni L
    Minerva Med; 2001 Apr; 92(2):121-7. PubMed ID: 11323574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methotrexate has no antifibrotic effect in bleomycin-induced experimental scleroderma.
    Ozgen M; Koca SS; Isik A; Ozercan IH
    J Rheumatol; 2010 Mar; 37(3):678-9. PubMed ID: 20197571
    [No Abstract]   [Full Text] [Related]  

  • 59. Thymoglobulin and cyclophosphamide as treatment for diffuse cutaneous systemic sclerosis.
    Holmberg LA; Furst DE; McSweeney PA; Nash RA
    J Rheumatol; 2009 Aug; 36(8):1839. PubMed ID: 19671826
    [No Abstract]   [Full Text] [Related]  

  • 60. [Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?].
    Verrecchia F; Michel L; Keshtmand H; Wang Y; Launay D; Farge D
    Rev Med Interne; 2009 Nov; 30(11):955-62. PubMed ID: 19349102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.